VANCOUVER, BC and PRINCETON, NJ /ACCESSWIRE /March 22, 2022/ Xybion Digital Inc. (TSXV: XYBN) (“Xybion” or the “Company”), a global, low-code SaaS company that enables digital transformation in highly regulated industries such as life sciences, today announced that She had been awarded a 5-year, multi-million US dollar contract by a leading global pharmaceutical company with branches in over 100 countries. Xybion is deploying the Pristima XD module to standardize and simplify lab operations for the customer. This victory reinforces Xybion’s leading position in the life sciences sector and validates the company’s strategy to expand its operations into new geographies globally.
“We are delighted to start working with one of the world’s largest pharmaceutical companies. This victory solidifies Xybion Digital’s track record as a trusted partner of large multinationals operating in the life sciences industry,” said Dr. Pradip Banerjee, President and CEO. CEO of Xybion Digital. “We are extremely proud to have been selected by this world-renowned pharmaceutical company as their partner for the digital acceleration of laboratory operations. Our low-code platform is perfectly suited to help life sciences companies meet the challenges of digital transformation, and we look forward to helping this group achieve its goals.”
About Xybion Digital Inc.
Xybion is a global SaaS company that helps life science companies accelerate the development of new drugs into approved medicines that can save lives and keep employees safe. We digitize drug research and development, laboratory testing, regulatory approvals, and pharmaceutical manufacturing on a single unified, cost-effective, ready-to-deploy, and easy-to-use cloud platform. Xybion has more than 160 customers in 29 countries who use its low-code software to accelerate turnaround times, improve compliance, expand capacity, minimize operational risk and reduce expenses while keeping employees safe.
Learn more about Xybion at https://www.xybion.com/
For more information: For more information regarding Xybion Digital Inc., please contact Pradip Banerjee, CEO, [email protected], 609-512-5790 x122
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Some statements (“forward-looking statements“) in this press release may contain forward-looking information regarding Xybion’s position in the life sciences industry, the services to be provided by Xybion as described above and their results, plans related to the Company’s business and other matters that may occur in the future, as of the date of this press release. In making the forward-looking statements included in this press release, the Company has applied several important assumptions, including that Xybion will be able to to provide its services as currently expected.While management considers these assumptions to be reasonable based on information available to it, they may prove to be incorrect.
Forward-looking statements are subject to a variety of known and unknown risks, uncertainties and other factors that could cause actual events or results to differ from those expressed or implied by the forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, as a number of important factors could cause actual results to differ materially from the expectations expressed therein. These factors include, among others, the risk that the Company may not be able to provide its services as currently anticipated, that the results of such services may not be consistent with the results anticipated or those described in the disclosure documents filed by the Company on SEDAR. There can be no assurance that forward-looking statements will prove to be accurate, and actual results and future events could differ materially from those anticipated in such statements. The Company expressly disclaims any intention or obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by applicable securities laws.
This press release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities described in the United States. The securities described herein have not been registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Law“), or any state securities law and may not be offered or sold in the “United States”, as that term is defined in Regulation S promulgated under the U.S. Securities Act, unless registered under the US Securities Act and applicable state securities laws or an exemption from such registration requirements is available.
THE SOURCE: Xybion Digital Inc.
See the source version on accesswire.com:
https://www.accesswire.com/694166/Xybion-Digital-Inc-is-Awarded-a-5-Year-Multi-Million-US-dollar-Contract-with-a-Leading-Global-Pharmaceutical-Company- Headquarters in Europe